1
|
Favier-Archinard C, Leguelinel-Blache G, Dubois F, Le Gall T, Bourquard P, Passemard N, Tora S, Rey A, Rossi M, Chevallier T, Cousin C, Favier M. [Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation]. Bull Cancer 2018; 105:475-485. [PMID: 29573809 DOI: 10.1016/j.bulcan.2017.12.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Revised: 11/28/2017] [Accepted: 12/18/2017] [Indexed: 11/18/2022]
Abstract
The safety of the community treatment with oral anticancer therapies is a strong theme of the cancer plan 2014-2019. The objective of this study was to develop a Pharmaceutical Counseling Guide to improve medication adherence in patients treated for multiple myeloma with oral anticancer therapies. A multidisciplinary professional working group selected a list of relevant medication adherence-related items that served as the framework for the design of the pharmaceutical counseling support materials in patient-accessible language. The readability, understanding and memorization of the information were validated in ten patients treated for myeloma. Twelve items were selected for treatment information (5 items), treatment planning (5 items), and adverse drug effects (2 items). A pharmacist guide, a patient guide, a medication schedule, and three self-questionnaires to evaluate medication knowledge and understanding of patients were developed. The patient test resulted in changes in these documents. This study carried out the initial validation of documents to standardize the pharmaceutical counseling for patients treated for myeloma so that it can be reproduced from one patient to another regardless of the pharmacist, by standardizing the information issued. This study needs to be completed by a final validation in myeloma patients, free from oral anticancer therapies.
Collapse
Affiliation(s)
- Camille Favier-Archinard
- Centre hospitalier universitaire Carémeau, service de pharmacie, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France
| | - Géraldine Leguelinel-Blache
- Centre hospitalier universitaire Carémeau, service de pharmacie, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France
| | - Florent Dubois
- Centre hospitalier universitaire Carémeau, service de pharmacie, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France
| | - Tanguy Le Gall
- Centre hospitalier universitaire Carémeau, service de pharmacie, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France
| | - Pascal Bourquard
- Institut Gardois de cancérologie, service d'hématologie clinique, 30900 Nîmes, France
| | - Nadège Passemard
- Institut de formation aux métiers de la santé, 30000 Nîmes, France
| | - Sandrine Tora
- Centre hospitalier universitaire Carémeau, service de pharmacie, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France
| | - Aurélie Rey
- Institut Gardois de cancérologie, service d'oncologie, 30900 Nîmes, France
| | - Marie Rossi
- Centre hospitalier universitaire Carémeau, Direction générale communication et culture, 30029 Nîmes cedex 9, France
| | - Thierry Chevallier
- Centre hospitalier universitaire Carémeau, laboratoire de biostatistique, épidémiologie, Santé publique, informatique médicale, 30029 Nîmes cedex 9, France
| | - Christelle Cousin
- Institut Gardois de cancérologie, unité pharmacie oncologique, 30900 Nîmes, France
| | - Mireille Favier
- Centre hospitalier universitaire Carémeau, service de pharmacie, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France.
| |
Collapse
|